Sign in

    Walgreens Boots Alliance Inc (WBA)

    You might also like

    No business description found.

    NamePositionStart DateShort Bio
    Stefano PessinaExecutive Chairman of the BoardMarch 2021Stefano Pessina has been serving as the Executive Chairman of the Board at Walgreens Boots Alliance since March 2021. He previously served as CEO from July 2015 to March 2021 and has been a director since April 2012 .
    Tim WentworthChief Executive OfficerOctober 23, 2023Timothy C. Wentworth has served as the CEO of WBA since October 23, 2023. He previously held leadership roles at Evernorth Health Services and Express Scripts .
    Manmohan MahajanExecutive Vice President and Global Chief Financial OfficerMarch 1, 2024Manmohan Mahajan has been the Executive Vice President and Global CFO at WBA since March 1, 2024. He was the Interim Global CFO from July 2023 to March 2024 and has held various roles at WBA since 2016 .
    Ornella BarraChief Operating Officer, InternationalApril 2021Ornella Barra has served as the Chief Operating Officer, International at WBA since April 2021. She was previously Co-Chief Operating Officer from June 2016 to April 2021 .
    Mary LangowskiExecutive Vice President and President, U.S. HealthcareMarch 2024Mary Langowski has been the Executive Vice President and President, U.S. Healthcare at WBA since March 2024. She was previously the CEO of Solera Health from July 2020 to March 2024 .
    Lanesha MinnixExecutive Vice President and Global Chief Legal OfficerApril 2024Lanesha Minnix has served as Executive Vice President and Global Chief Legal Officer at WBA since April 2024. She was previously the Executive Vice President, General Counsel, and Corporate Secretary for Ecolab Inc. .
    Elizabeth BurgerExecutive Vice President and Global Chief Human Resources OfficerMarch 2024Elizabeth Burger has been the Executive Vice President and Global Chief Human Resources Officer at WBA since March 2024. She was previously the Senior Vice President and Chief Human Resources Officer at Flowserve Corporation .
    Neal SampleExecutive Vice President and Chief Information OfficerOctober 2023Neal Sample has served as Executive Vice President and Chief Information Officer at WBA since October 2023. He was previously the CIO at Northwestern Mutual .
    Tracey BrownExecutive Vice President and President, Retail and Chief Customer OfficerJanuary 2024Tracey Brown has served as Executive Vice President and President, Retail and Chief Customer Officer at WBA since January 2024. She was previously the Senior Vice President and President of Retail Products and Chief Customer Officer .
    Rick GatesSenior Vice President and Chief Pharmacy OfficerMarch 2023Rick Gates has been the Senior Vice President and Chief Pharmacy Officer at WBA since March 2023. He has been with Walgreens since 1995, holding various roles .
    Beth LeonardSenior Vice President and Chief Corporate Affairs OfficerJanuary 2024Beth Leonard has served as Senior Vice President and Chief Corporate Affairs Officer at WBA since January 2024. She was previously the Senior Vice President and Chief Communications Officer from June 2023 to January 2024 .
    William H. Shrank, M.D.Board MemberSeptember 1, 2024William H. Shrank, M.D., was appointed to the Board of Directors of WBA effective September 1, 2024. He is a venture partner with the Bio + Health Team of Andreessen Horowitz and has extensive experience in healthcare .
    1. Given your plan to close approximately 1,200 stores over the next three years, how do you anticipate this will impact your market share and what specific strategies are in place to retain customers from these underperforming locations?

    2. You mentioned the need to stabilize pharmacy margins and address reimbursement pressures; can you elaborate on the concrete steps you're taking to negotiate better terms with PBMs and how confident you are in achieving sustainable reimbursement rates?

    3. With the reorientation to a retail pharmacy-led model and investments planned for higher-performing stores, how will you differentiate Walgreens from competitors who have already invested in similar capabilities, and what is your timeline for closing this competitive gap?

    4. Considering the ongoing challenges with consumer price sensitivity and declining retail sales, especially in non-essential categories, what specific initiatives are you implementing to drive retail growth and improve gross margins without relying solely on cost-cutting measures?

    5. Regarding your intention to monetize non-core assets like VillageMD to strengthen your balance sheet, how will this divestiture affect your long-term healthcare strategy, and what are the potential risks to your growth prospects in the U.S. Healthcare segment?

    Program DetailsProgram 1
    Approval DateJune 2018
    End Date/DurationNo specified expiration date
    Total additional amount$10.0 billion
    Remaining authorization$2.0 billion as of August 31, 2024
    DetailsThe program aims to offset anticipated dilution from equity incentive plans. It was suspended in July 2020, but there is no specified expiration date, and the company may continue repurchases.
    YearAmount Due [Billions]Debt TypeInterest Rate [%]% of Total Debt
    20250.446Short-term debtN/A5.5% = (0.446 / 8.1) * 100
    20252.4Operating lease obligationsN/A29.6% = (2.4 / 8.1) * 100
    20250.091Finance lease obligationsN/A1.1% = (0.091 / 8.1) * 100
    20262.8Long-term debt2.12534.6% = (2.8 / 8.1) * 100
    20271.8Long-term debtN/A22.2% = (1.8 / 8.1) * 100

    Competitors mentioned in the company's latest 10K filing.

    • Chain and independent pharmacies
    • Mail order prescription providers
    • Grocery stores
    • Convenience stores
    • Mass merchants
    • Online and omni-channel pharmacies and retailers
    • Warehouse clubs
    • Dollar stores
    • Other discount merchandisers
    • Pharmaceutical wholesalers
    • Importers and manufacturers who supply directly to pharmacies
    • Retail healthcare services
    • Urgent care services
    • Value-based primary care
    • Vertically integrated providers
    • Post-acute and home health service providers
    • Virtual care companies
    NameStart DateEnd DateReason for Change
    Deloitte & Touche LLP2002 PresentCurrent auditor

    Recent developments and announcements about WBA.

    Financial Reporting

      Earnings Call

      ·
      Jan 10, 2025, 4:00 PM

      The Walgreens Boots Alliance (WBA) recently released its earnings call transcript for the first quarter of fiscal year 2025. Below is a summary of the key points:

      Revenue and Profit Performance

      • Sales Growth: Sales increased by 6.9% on a constant currency basis, with growth across all segments.
      • Adjusted EPS: Adjusted earnings per share (EPS) was $0.51, a 23% decline year-over-year, primarily due to prior-year sale-leaseback gains and lower equity income from Cencora.
      • Segment Performance:
        • U.S. Healthcare sales grew by 12%, driven by VillageMD and Shields Health Solutions.
        • U.S. Retail Pharmacy comparable sales grew by 8.5%, supported by pharmacy sales, though retail sales declined.
        • International sales increased by 6.5%, with strong performance from Boots UK and Germany.

      Management’s Forward Guidance

      • Turnaround Strategy: Management emphasized its commitment to a retail pharmacy-led turnaround, focusing on financial discipline, store closures, and operational improvements.
      • Adjusted EPS Guidance: The company reaffirmed its fiscal 2025 adjusted EPS guidance of $1.40 to $1.80, despite challenges in the U.S. retail environment.
      • Cash Flow: WBA improved free cash flow through reduced capital expenditures and higher adjusted operating income. The company remains focused on long-term positive cash flow generation.

      Market Conditions and Strategic Initiatives

      • Consumer Behavior: Persistent inflation and higher interest rates have pressured consumer discretionary spending, impacting retail sales.
      • Store Closures: WBA plans to close approximately 500 stores in fiscal 2025 as part of its Footprint Optimization Program, which is expected to yield $100 million in annual operating income benefits.
      • Healthcare Growth: Shields Health Solutions and VillageMD showed strong growth, with Shields achieving a 30% sales increase.
      • Reimbursement Adjustments: WBA has renegotiated contracts for 2025 to better align reimbursement with costs, including creating new categories for high-cost drugs and rebalancing brand and generic drug reimbursements.

      Analyst Questions and Management Responses

      • Free Cash Flow Confidence: Management expressed confidence in achieving positive free cash flow for the year, citing improved working capital and reduced capital expenditures.
      • Micro Fulfillment Centers (MFCs): WBA plans to expand its MFC network to serve 6,000 stores by the end of 2025, improving operational efficiency and enabling pharmacists to focus on higher-value activities.
      • Retail Strategy: The company is introducing new product categories (e.g., women’s wellness, superfoods) and enhancing its omnichannel capabilities to adapt to changing consumer preferences.

      Key Analyst Topics

      • Reimbursement Risk: Analysts inquired about the impact of new reimbursement models on pharmacy costs. Management highlighted that the changes aim to realign risk and ensure fair compensation for services.
      • Script Retention: WBA reported better-than-expected script retention rates in stores undergoing closures, which supports its strategy to consolidate operations.

      Conclusion

      WBA is making progress on its turnaround strategy, focusing on operational improvements, cost management, and strategic realignments in reimbursement and retail. While challenges remain, particularly in the U.S. retail market, the company is optimistic about its long-term growth and profitability.

      For further details, refer to the full earnings call transcript.

      Earnings Report

      ·
      Jan 10, 2025, 12:46 PM

      Walgreens Boots Alliance (WBA) Releases Fiscal 2025 Q1 Earnings Results

      Walgreens Boots Alliance (WBA) has announced its financial results for the first quarter of fiscal 2025, which ended on November 30, 2024. Below are the key highlights:

      Financial Performance

      • Sales Growth: First-quarter sales increased by 7.5% year-over-year to $39.5 billion, with a 6.9% increase on a constant currency basis.
      • Net Loss: The company reported a net loss of $265 million, compared to a net loss of $67 million in the same quarter last year. This was primarily driven by higher operating losses.
      • Loss Per Share: Loss per share was $0.31, compared to a loss of $0.08 in the year-ago quarter.
      • Adjusted EPS: Adjusted earnings per share (EPS) were $0.51, down from $0.66 in the prior year, reflecting a 23.4% decrease on a constant currency basis.

      Segment Highlights

      U.S. Retail Pharmacy

      • Sales: Increased by 6.6% to $30.9 billion, with comparable sales up 8.5%.
      • Pharmacy Sales: Grew by 10.4%, driven by higher branded drug inflation and prescription volume.
      • Retail Sales: Declined by 6.2%, reflecting weaker demand in discretionary categories and a softer cough, cold, and flu season.
      • Adjusted Operating Income: Decreased by 36.4% to $441 million, primarily due to lower retail sales and the absence of prior-year sale-leaseback gains.

      International Segment

      • Sales: Increased by 10.2% to $6.4 billion, with a 6.5% increase on a constant currency basis.
      • Boots UK Performance: Comparable pharmacy sales rose by 10.9%, while retail sales grew by 8.1%, supported by strong Black Friday performance and a 30% increase in Boots.com sales.
      • Adjusted Operating Income: Increased by 17.9% to $168 million, driven by strong retail performance in the UK and growth in Germany.

      U.S. Healthcare

      • Sales: Reached $2.2 billion, with growth across all businesses, including 9% growth in VillageMD, 16% in CareCentrix, and 30% in Shields.
      • Operating Loss: Narrowed to $325 million from $436 million in the prior year, reflecting improved performance at VillageMD and Shields.
      • Adjusted EBITDA: Improved to $70 million, up $109 million from the prior year.

      Strategic Priorities and Guidance

      • Fiscal 2025 Guidance: The company maintained its adjusted EPS guidance of $1.40 to $1.80 for the full fiscal year. Growth in U.S. Healthcare and International segments is expected to offset declines in U.S. Retail Pharmacy.
      • Cost Management: CEO Tim Wentworth emphasized progress in optimizing the company’s footprint, controlling costs, and improving cash flow as part of its turnaround strategy.

      Cash Flow and Investments

      • Operating Cash Flow: Net cash used for operating activities was $140 million, a $141 million improvement compared to the prior year.
      • Free Cash Flow: Negative $424 million, reflecting a $363 million improvement due to reduced capital expenditures and higher adjusted operating income.

      Conference Call

      WBA will host a conference call today, January 10, 2025, at 8:30 a.m. Eastern Time to discuss these results. A replay will be available on the company’s investor relations website.

      Key Takeaways

      While WBA continues to face challenges in its U.S. Retail Pharmacy segment, the company is making progress in its healthcare and international businesses. The focus on cost savings and strategic initiatives is expected to support its turnaround efforts in the coming quarters.


      Sources: , ,